WASHINGTON, DC – The Health Subcommittee, chaired by Rep. Michael C. Burgess, M.D. (R-TX), today scheduled a hearing for Tuesday, January 30, 2018, at 11 a.m. in room 2123 of the Rayburn House Office Building. The hearing is entitled, “Examining Implementation of the Compounding Quality Act.”
#SubHealth will examine the U.S. Food and Drug Administration’s (FDA) implementation of Title I of the Drug Quality and Security Act (DQSA), which was enacted nearly five years ago in the wake of the fungal meningitis outbreak caused by the New England Compounding Center. At that time, the DQSA established heightened safeguards for compounded medications, as well as new avenues for entities to engage in compounding of medications.
“Certain patient populations rely on access to safe and appropriate compounding of medications that can be customized for their unique health care needs,” said Chairman Burgess. “The subcommittee will hear directly from FDA, pharmacies, physicians, patients, and others, to get a status update on implementing the compounding provisions in DQSA thus far.”
The Majority Memorandum, witness list, and witness testimony for the hearing will be available here as they are posted.